Scienture Holdings, Inc. (SCNX) reported its year-end 2025 financial results, highlighting significant revenue growth, improved gross margins and expanded commercial reach across its pharmaceutical portfolio.
The company, which operates branded specialty pharmaceutical and wholesale businesses, said 2025 marked a transformational year driven by the commercial launch of Arbli, its ready-to-use epinephrine injection for the treatment of allergic reactions (Type I), including anaphylaxis, and continued progress with REZENOPY, its high-dose naloxone nasal spray for the emergency treatment of known or suspected opioid overdose.
For the full year 2025, net revenue rose 216% to $431,609 from $136,643 in 2024, supported by initial sales of Arbli following its FDA approval and launch in the third quarter.
Gross margin expanded sharply to 76.8%, up from 4.4% in the prior year, reflecting a shift toward higher-margin branded pharmaceutical products. Excluding a one-time non-cash impairment charge of $26.3 million, net loss from continuing operations improved by approximately $37,000 year-over-year.
As of December 31, 2025, Scienture had $6.7 million in cash and cash equivalents and positive working capital of $5.2 million.
Management said the company strengthened its commercial footprint through PBM-led and institutional GPO agreements, expanding access for Arbli to more than 2,500 U.S. healthcare institutions and securing formulary inclusion with major national health plans covering over 100 million lives.
The company also advanced REZENOPY, receiving an Orange Book-listable patent and formalizing GPO agreements that extend access to more than 5,000 healthcare institutions, representing roughly 60% of the U.S. institutional market. Scienture said it expects 2026 to reflect continued momentum for Arbli and the planned commercial launch of REZENOPY in the second quarter of the year.
SCNX has traded between $0.24 and $2.60 over the past year. The stock is currently trading at $0.27, down 36.83%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.